Table 1 Demographic and baseline characteristics of patients with systemic lupus erythematosus (SLE) and matched non-SLE comparators from the Lupus Midwest Network registry on January 1, 2015

Age, years, mean (SD)

54.0 (15.6)

54.1 (15.7)

0.97

Women, n (%)

359 (81.6)

355 (82.6)

0.71

Race/ethnicity, n (%)

0.99

 Non-Hispanic White

387 (88.0)

377 (87.7)

 Hispanic

19 (4.3)

17 (4.0)

 Black

13 (3.0)

15 (3.5)

 Asian

15 (3.4)

14 (3.3)

 American Indian

2 (0.5)

2 (0.5)

 Other/mixed

4 (0.9)

5 (1.2)

Smoking, n (%)

0.15

 Current^b

83 (21.0)

90 (26.4)

 Former^b

158 (39.9)

117 (34.3)

 Never^b

155 (39.1)

134 (39.3)

 Missing

44

89

BMI, kg/m², mean (SD)

29.3 (7.5)

29.9 (7.1)

0.094

 BMI ≥30kg/m^2b, n (%)

161 (38.1)

155 (40.1)

0.56

 BMI ≥40kg/m^2b, n (%)

40 (9.5)

36 (9.3)

0.94

 Missing

17

43

ADI, mean (SD)

94.1 (12.6)

93.8 (12.2)

0.76

Charlson Comorbidity Index ^c, mean (SD)

2.3 (2.6)

0.9 (1.6)

<0.001

 Breast cancer^d

15 (4.2)

12 (3.4)

0.58

 Cervical cancer^d

8 (2.2)

2 (0.6)

0.058

 Other gynecological cancer^d

2 (0.6)

1 (0.3)

0.57

 Hypertension

221 (50.2)

151 (35.1)

<0.001

 Hyperlipidemia

173 (39.3)

164 (38.1)

0.72

 Diabetes mellitus

42 (9.5)

40 (9.3)

0.90

 Osteoporosis

72 (16.4)

20 (4.7)

<0.001

 Glucocorticoids

328 (74.5)

110 (25.6)

<0.001

 ≥90 days

283 (64.3)

29 (6.7)

<0.001

 <90 days

45 (10.2)

81 (18.8)

<0.001

 Antiosteoporotic

69 (15.7)

19 (4.4)

<0.001

 Hyperlipidemia therapy

122 (27.7)

121 (28.1)

0.89